Literature DB >> 23364341

Role of STAT3 in angiotensin II-induced hypertension and cardiac remodeling revealed by mice lacking STAT3 serine 727 phosphorylation.

Fouad A Zouein1, Carlos Zgheib, Shereen Hamza, John W Fuseler, John E Hall, Andrea Soljancic, Arnaldo Lopez-Ruiz, Mazen Kurdi, George W Booz.   

Abstract

STAT3 is involved in protection of the heart provided by ischemic preconditioning. However, the role of this transcription factor in the heart in chronic stresses such as hypertension has not been defined. We assessed whether STAT3 is important in hypertension-induced cardiac remodeling using mice with reduced STAT3 activity due to a S727A mutation (SA/SA). Wild type (WT) and SA/SA mice received angiotensin (ANG) II or saline for 17 days. ANG II increased mean arterial and systolic pressure in SA/SA and WT mice, but cardiac levels of cytokines associated with heart failure were increased less in SA/SA mice. Unlike WT mice, hearts of SA/SA mice showed signs of developing systolic dysfunction as evidenced by reduction in ejection fraction and fractional shortening. In the left ventricle of both WT and SA/SA mice, ANG II induced fibrosis. However, fibrosis in SA/SA mice appeared more extensive and was associated with loss of myocytes. Cardiac hypertrophy as indexed by heart to body weight ratio and left ventricular anterior wall dimension during diastole was greater in WT mice. In WT+ANG II mice there was an increase in the mass of individual myofibrils. In contrast, cardiac myocytes of SA/SA+ANG II mice showed a loss in myofibrils and myofibrillar mass density was decreased during ANG II infusion. Our findings reveal that STAT3 transcriptional activity is important for normal cardiac myocyte myofibril morphology. Loss of STAT3 may impair cardiac function in the hypertensive heart due to defective myofibrillar structure and remodeling that may lead to heart failure.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23364341      PMCID: PMC3674130          DOI: 10.1038/hr.2012.223

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  35 in total

1.  Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation.

Authors:  Michael W Brands; Amy K L Banes-Berceli; Edward W Inscho; Hind Al-Azawi; Ashlyn J Allen; Hicham Labazi
Journal:  Hypertension       Date:  2010-10-04       Impact factor: 10.190

2.  Cardiac lineage protein-1 (CLP-1) regulates cardiac remodeling via transcriptional modulation of diverse hypertrophic and fibrotic responses and angiotensin II-transforming growth factor β (TGF-β1) signaling axis.

Authors:  Eduardo Mascareno; Josephine Galatioto; Inna Rozenberg; Louis Salciccioli; Haroon Kamran; Jason M Lazar; Fang Liu; Thierry Pedrazzini; M A Q Siddiqui
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

3.  Fractal and image analysis of morphological changes in the actin cytoskeleton of neonatal cardiac fibroblasts in response to mechanical stretch.

Authors:  John W Fuseler; Clarke F Millette; Jeffery M Davis; Wayne Carver
Journal:  Microsc Microanal       Date:  2007-04       Impact factor: 4.127

4.  Angiotensin II utilizes Janus kinase 2 in hypertension, but not in the physiological control of blood pressure, during low-salt intake.

Authors:  Amy K L Banes-Berceli; Hind Al-Azawi; Daniel Proctor; Harvey Qu; Dominic Femminineo; Crystal Hill-Pyror; R Clinton Webb; Michael W Brands
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-08-03       Impact factor: 3.619

Review 5.  Cytoprotection by the modulation of mitochondrial electron transport chain: the emerging role of mitochondrial STAT3.

Authors:  Karol Szczepanek; Qun Chen; Andrew C Larner; Edward J Lesnefsky
Journal:  Mitochondrion       Date:  2011-09-10       Impact factor: 4.160

6.  Cardiac-specific deletion of SOCS-3 prevents development of left ventricular remodeling after acute myocardial infarction.

Authors:  Toyoharu Oba; Hideo Yasukawa; Masahiko Hoshijima; Ken-ichiro Sasaki; Nobuyoshi Futamata; Daisuke Fukui; Kazutoshi Mawatari; Takanobu Nagata; Sachiko Kyogoku; Hideki Ohshima; Tomoko Minami; Keiichiro Nakamura; Dongchon Kang; Toshitaka Yajima; Kirk U Knowlton; Tsutomu Imaizumi
Journal:  J Am Coll Cardiol       Date:  2012-02-28       Impact factor: 24.094

7.  Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction.

Authors:  Hajime Morimoto; Masafumi Takahashi; Atsushi Izawa; Hirohiko Ise; Minoru Hongo; Pappachan E Kolattukudy; Uichi Ikeda
Journal:  Circ Res       Date:  2006-09-21       Impact factor: 17.367

8.  Relationship between circulating levels of monocyte chemoattractant protein-1 and systolic dysfunction in patients with hypertrophic cardiomyopathy.

Authors:  Jun Iwasaki; Kazufumi Nakamura; Hiromi Matsubara; Yoichi Nakamura; Nobuhiro Nishii; Kimikazu Banba; Masato Murakami; Keiko Ohta-Ogo; Hideo Kimura; Norihisa Toh; Satoshi Nagase; Takefumi Oka; Hiroshi Morita; Kengo Fukushima Kusano; Tohru Ohe
Journal:  Cardiovasc Pathol       Date:  2009-02-11       Impact factor: 2.185

9.  Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation.

Authors:  Yuhong Shen; Karni Schlessinger; Xuejun Zhu; Eric Meffre; Fred Quimby; David E Levy; J E Darnell
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

10.  IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2.

Authors:  Buddhadeb Dawn; Yu-Ting Xuan; Yiru Guo; Arash Rezazadeh; Adam B Stein; Greg Hunt; Wen-Jian Wu; Wei Tan; Roberto Bolli
Journal:  Cardiovasc Res       Date:  2004-10-01       Impact factor: 10.787

View more
  19 in total

1.  Angiotensin II receptor blocker irbesartan attenuates cardiac dysfunction induced by myocardial infarction in the presence of renal failure.

Authors:  Ryo Watanabe; Jun-Ichi Suzuki; Kouji Wakayama; Hidetoshi Kumagai; Yuichi Ikeda; Hiroshi Akazawa; Issei Komuro; Mitsuaki Isobe
Journal:  Hypertens Res       Date:  2015-12-10       Impact factor: 3.872

Review 2.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

3.  Oncogenic dependency on STAT3 serine phosphorylation in KRAS mutant lung cancer.

Authors:  Sultan Alhayyani; Louise McLeod; Alison C West; Jesse J Balic; Christopher Hodges; Liang Yu; Julian A Smith; Zdenka Prodanovic; Steven Bozinovski; Beena Kumar; Saleela M Ruwanpura; Mohamed I Saad; Brendan J Jenkins
Journal:  Oncogene       Date:  2021-12-03       Impact factor: 9.867

4.  Human monocyte transcriptional profiling identifies IL-18 receptor accessory protein and lactoferrin as novel immune targets in hypertension.

Authors:  Matthew R Alexander; Allison E Norlander; Fernando Elijovich; Ravi V Atreya; Amadou Gaye; Juan S Gnecco; Cheryl L Laffer; Cristi L Galindo; Meena S Madhur
Journal:  Br J Pharmacol       Date:  2018-06-21       Impact factor: 8.739

5.  The nuclear receptor RORα protects against angiotensin II-induced cardiac hypertrophy and heart failure.

Authors:  Ju Youn Beak; Hong Soon Kang; Wei Huang; Page H Myers; Dawn E Bowles; Anton M Jetten; Brian C Jensen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-11-02       Impact factor: 4.733

6.  βIV-Spectrin regulates STAT3 targeting to tune cardiac response to pressure overload.

Authors:  Sathya D Unudurthi; Drew Nassal; Amara Greer-Short; Nehal Patel; Taylor Howard; Xianyao Xu; Birce Onal; Tony Satroplus; Deborah Hong; Cemantha Lane; Alyssa Dalic; Sara N Koenig; Adam C Lehnig; Lisa A Baer; Hassan Musa; Kristin I Stanford; Sakima Smith; Peter J Mohler; Thomas J Hund
Journal:  J Clin Invest       Date:  2018-11-12       Impact factor: 14.808

7.  Resistin induces cardiac fibroblast-myofibroblast differentiation through JAK/STAT3 and JNK/c-Jun signaling.

Authors:  Rajvir Singh; Ravinder K Kaundal; Baoyin Zhao; Rihab Bouchareb; Djamel Lebeche
Journal:  Pharmacol Res       Date:  2021-01-29       Impact factor: 7.658

8.  The STAT3-Ser/Hes3 signaling axis: an emerging regulator of endogenous regeneration and cancer growth.

Authors:  Steven W Poser; Deric M Park; Andreas Androutsellis-Theotokis
Journal:  Front Physiol       Date:  2013-10-01       Impact factor: 4.566

Review 9.  Emerging therapeutic targets for cardiac arrhythmias: role of STAT3 in regulating cardiac fibroblast function.

Authors:  Nehal J Patel; Drew M Nassal; Daniel Gratz; Thomas J Hund
Journal:  Expert Opin Ther Targets       Date:  2020-11-23       Impact factor: 6.902

Review 10.  Pivotal Importance of STAT3 in Protecting the Heart from Acute and Chronic Stress: New Advancement and Unresolved Issues.

Authors:  Fouad A Zouein; Raffaele Altara; Qun Chen; Edward J Lesnefsky; Mazen Kurdi; George W Booz
Journal:  Front Cardiovasc Med       Date:  2015-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.